← Back to Search

Bcl-2 Inhibitor

Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in the Treatment of Myelofibrosis With Myeloid Metaplasia

Phase 2
Waitlist Available
Research Sponsored by Gemin X
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

Defects in the apoptotic process can lead to the onset of cancer by allowing cells to grow unchecked when an oncogenic signal is present. Obatoclax is designed to restore apoptosis through inhibition of the Bcl-2 family of proteins, thereby reinstating the natural process of cell death that is often inhibited in cancer cells.

Eligible Conditions
  • Myelofibrosis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: GX15-070MSExperimental Treatment1 Intervention
Obatoclax mesylate 60mg
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Obatoclax
Not yet FDA approved

Find a Location

Who is running the clinical trial?

Gemin XLead Sponsor
12 Previous Clinical Trials
425 Total Patients Enrolled
Jean Viallet, MDStudy DirectorGemin X, Inc.
8 Previous Clinical Trials
397 Total Patients Enrolled
~1 spots leftby Jan 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top